Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest added to Nvidia (revenue +106% to $96.2B; adjusted EPS +120% to $2.22) and Broadcom (Q2 revenue growth accelerating to 48%, guided for ~85% growth) after strong earnings, though both stocks fell on Friday after initial post-earnings strength. Nvidia’s FY2028 revenue growth guidance is 70% vs ~45% expectations, lifting next-year EPS estimates from $13.01 to $15.31 and putting the stock around 14x next-year earnings. Intellia Therapeutics was also added despite remaining unprofitable and a reported pause in a Phase 3 liver-toxicity signal, with an Evercore ISI $24 price target nearly double the current level.

Analysis

The useful signal here is not the buy list itself; it is that the market is still paying up for AI infrastructure despite a recent factor wobble. NVDA remains the cleanest lever to hyperscaler capex, but the bigger second-order winner is AVGO if customers keep shifting toward custom silicon, networking, and integration spend rather than discrete accelerator purchases. That mix can support a higher quality multiple than peers because it monetizes more layers of the stack, not just unit shipments.

Near term, Friday weakness looks more like positioning reset than thesis damage. Over 1-3 months, the key catalyst is whether next earnings prints confirm that growth is broadening beyond one or two hyperscalers; if not, the market can still compress multiples even at 14x-19x forward earnings. The falsifier for the bull case is not valuation; it is any sign that capex cadence flattens or that margins start giving back to maintain share.

NTLA is a different animal: the opportunity is binary clinical optionality, while the risk is a long information vacuum after a safety-related trial pause. In a tape where ARKG can support momentum names, flow can help the stock bounce, but it does not remove the financing-overhang and dilution risk if timelines slip. The consensus is probably overrating "cash-rich" as a shield; in this part of biotech, time is the real balance-sheet risk.

Key Decisions for Investors

• Buy NVDA on 3-5% pullbacks over the next 1-2 weeks; target 15-20% relative upside vs SOXX over 1-3 months, with a stop if next-quarter revenue growth guide falls materially below current expectations.
• After AVGO reports, buy weakness only if management confirms AI growth acceleration and keeps next-year growth above the current high-80% setup; use AVGO/SOXX as a cleaner expression than outright beta.
• Use a defined-risk AVGO call spread into Wednesday only if implied move is below the stock's historical post-earnings swing; otherwise wait for the print and fade any knee-jerk de-risking.
• Avoid chasing NTLA; if you want exposure to the gene-editing rerating, short NTLA on spikes or pair short NTLA vs long XBI until the phase 3 pause is resolved and safety risk is de-risked.
• Set a watch item on hyperscaler capex commentary and NVDA/AVGO forward gross margin; a single guide cut or margin reset would likely matter more than another beat.